Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APB-R3

• Status: Not yet recruiting
• Trial end date: 2023-11-03
• Target enrollment: 0
• Participant gender: All

Summary

This will be a single centre, Phase 1, First-In-Human, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Dose of APB-R3 in Healthy Participants.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Syneos Health
• Collaborator: AprilBio Co., Ltd.

Criteria

Inclusion Criteria:

1. Male or female, non-smoker, 18 to 60 years of age (both inclusive),

2. Healthy as defined by:

1. the absence of clinically significant illness and surgery within 4 weeks prior to study drug administration in the opinion of the investigator.

2. the absence of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease in the opinion of the investigator.

Exclusion Criteria:

1. Abnormal finding at physical examination

2. Evidence of clinical significant hepatic or renal impairment

3. Clinically significant abnormal laboratory test results or positive serology test results for HBsAg, HCV antibody, or HIV antigen and antibody, or positive test results for COVID-19, or QuantiFERON®-TB test at screening.

4. Any reason which, in the opinion of the Investigator, would prevent the participant from participating in the study.